EGFR and cancer: ASP-RNAi treatment allows for suppression of cancer cells regardless of the sensitivity of the cells to EGFR-TKIs (Figure 1D and Figure S2); this is because RNAi silencing is mechanistically different from EGFR-TKI-mediated inhibition, and the feature of ASP-RNAi may permit an anticancer therapy for patients with cancers resistant to EGFR-TKIs.